Patent expiry and costs for anti-cancer medicines for clinical use : expiry and costs anti-cancer medicines

Godman, Brian and Wild, Claudia and Haycox, Alan (2017) Patent expiry and costs for anti-cancer medicines for clinical use : expiry and costs anti-cancer medicines. Generics and Biosimilars Initiative journal. pp. 1-3. ISSN 2033-6403 (In Press)

[img]
Preview
 Text (Godman-etal-GABI-2017-Patent-expiry-and-costs-for-anti-cancer-medicines-for-clinical)
Godman_etal_GABI_2017_Patent_expiry_and_costs_for_anti_cancer_medicines_for_clinical.pdf
Accepted Author Manuscript
Download (235kB)| Preview

    Abstract

    Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the patent expiry of (non-) tyrosine kinase inhibitors.

    Author(s):Godman, Brian, Wild, Claudia and Haycox, Alan
    Item type:Article
    ID code:60241
    Keywords:anti cancer medicines, medicine patents, tyrosine kinase inhibitors, Pharmacy and materia medica, Pharmacology, Toxicology and Pharmaceutics(all)
    Subjects:Medicine > Pharmacy and materia medica
    Department:Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
    Depositing user: Pure Administrator
    Date deposited:20 Mar 2017 10:18
    Last modified:18 Sep 2019 01:02
    Related URLs:
    URI:https://strathprints.strath.ac.uk/id/eprint/60241
    Export data:
    CORE (COnnecting REpositories)